Business Wire

LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery

13.7.2026 08:16:00 CEST | Business Wire | Press Release

Share

LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows.

LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains.

The three strategic focus areas of partnership include:

  • LTM BlueVerse: AI Delivery Fabric
    LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Site Reliability Engineering (SRE), Observability, and Chaos Engineering.
  • LTM AI1000: Talent Enablement program
    LTM will also scale its AI1000 initiative to train and deploy thousands of Claude-certified architects and Forward Deployed Engineers (FDEs) who can work with clients from assessment and architecture through assessment, implementation, and continuous improvement.
  • Claude Center of Excellence (CoE)
    LTM will establish a dedicated Center of Excellence (CoE) for Claude as the partnership's scale engine – to build reusable Skills, agentic MVPs, reference architectures, and playbooks spanning cloud-native and platform-based applications. The CoE will provide governance backbone across responsible use, agent lifecycle, model governance, and data-privacy/residency compliance. It will also keep delivery aligned with Claude's evolving capabilities.

"LTM brings delivery expertise, trained people, and long-standing client relationships across industries, and their customers want to embed Claude into the systems they rely on. LTM is embedding Claude and Claude Code in BlueVerse, bringing trusted frontier AI technology to the center of how they do what they do best - help their clients build, modernize, and run their software," said Chris Ciauri, Managing Director of International, Anthropic.

“LTM helps clients accelerate AI adoption and translate AI investments into measurable business outcomes through our partnership with Anthropic. Combining Claude with LTM’s BlueVerse ecosystem, deep domain expertise, technology capabilities, and AI1000 talent initiative creates a powerful foundation for enterprises to embed AI across their business and modernize at scale,” said Venu Lambu, CEO and Managing Director, LTM.

The partnership will include joint go-to-market initiatives focussed on measurable business outcomes. LTM will also scale internal adoption by embedding Claude, Claude Code, and Claude Cowork into its delivery model to establish consistent adoption patterns and market-leading productivity benchmarks across the SDLC, with autonomous learning feedback into the Claude CoE and BlueVerse ecosystem.

About LTM

LTM — a Larsen & Toubro Group Company — is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation, and business AI — enabling new ways of working, new productivity paradigms, and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for our clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260712251521/en/

Contacts

Media Contact: Shambhavi Revandkar | Global Media Relations |
Shambhavi.revandkar@ltm.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 10:00:00 CEST | Press Release

Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 10:00:00 CEST | Press Release

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi

Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 09:30:00 CEST | Press Release

Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h

Sofinnova Partners Appoints David Evans as Partner13.7.2026 08:00:00 CEST | Press Release

Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products13.7.2026 01:00:00 CEST | Press Release

Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a fractionation license granted to Takeda by the Ministry of Health (MoH), the collaboration is a major milestone in advancing Indonesia’s health resilience and biopharmaceutical manufacturing capabilities. “This initiative reflects Indonesia’s commitment to building strategic healthcare capabilities and ensuring sustainable access to essential and innovative therapies for Indonesian patients,” said Minister Budi Gunadi Sadikin, Ministry of Health, Republic of Indonesia. “By working closely with trusted global partners like Takeda, we can accelerate the development o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye